Blocking oncogenic Ras signaling for cancer therapy

Journal of the National Cancer Institute

Volumn 93, Issue 14, 2001, Pages 1062-1074

  Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID; 2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTISENSE OLIGONUCLEOTIDE; BMS 186511; CISPLATIN; CYCLOPHOSPHAMIDE; FARNESYL TRANS TRANSFERASE; FLUOROURACIL; GEMCITABINE; GENE PRODUCT; GUANINE NUCLEOTIDE BINDING PROTEIN; ISIS 2503; L 731735; L 778123; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOMER; PACLITAXEL; PD 169451; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; RECEPTOR; TIPIFARNIB; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; APOPTOSIS; BIOCHEMISTRY; BLADDER CARCINOMA; CANCER; CANCER THERAPY; CARCINOGENESIS; CARDIOTOXICITY; CELL NUCLEUS; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DRUG TARGETING; ENZYME ACTIVATION; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MAMMAL CELL; MELANOMA; MOUSE; NEUTROPENIA; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PANCREAS CANCER; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; THYROID CARCINOMA;

EID: 0035908493     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.14.1062     Document Type: Review

References (175)

1. Ras genes
2. The ras protein family: Evolutionary tree and role of conserved amino acids
3. Proteins regulating Ras and its relatives
4. Ras-effector interactions, the problem of specificity
5. Regulation of the mevalonate pathway
6. Enzymatic modification of proteins with a geranylgeranyl isoprenoid
7. A protein geranylgeranyltransferase from bovine brain: Implications for protein prenylation specificity
8. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues
9. Rab geranylgeranyl transferase. A multisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys
10. Rab geranylgeranyl transferase catalyzes the geranylgeranylation of adjacent cysteines in the small GTPases Rab1A, Rab3A, and Rab5A
11. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity
12. Friends and family: The role of the Rab GTPases in vesicular traffic
13. Protein prenylation: Molecular mechanisms and functional consequences
14. Posttranslational modification of the Ha-ras oncogene protein: Evidence for a third class of protein carboxyl methyltransferases
15. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B)
16. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor
17. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants
18. Regulation of the ras signaling network
19. Regulation of the Ras signaling network
20. Ras oncogenes in human cancer: A review
21. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts
22. Transgenic models of tumor development
23. Prevalence of ras gene mutations in human colorectal cancers
24. Ha-ras oncogenes are activated by somatic alterations in human urinary tract tumours
25. Preferential and novel activation of H-ras in human bladder carcinomas
26. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras
27. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation
28. Synergistic effect of the v-myc oncogene with H-ras on radio-resistance
29. Increased radioresistance of EJras-transformed human osteosarcomal cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation
30. Sensitivity to ionising radiation of transformed human cells containing mutant ras genes
31. RAS and leukemia: From basic mechanisms to gene-directed therapy
32. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis
33. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer
34. Mutations of Ki-ras and p53 genes in colorectal cancer and their prognostic significance
35. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study
36. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study
37. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer
38. Detection of K-ras mutations in lung carcinomas: Relationship to prognosis
39. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women
40. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: A combined analysis of 881 cases
41. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer
42. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer
43. Increasing complexity of Ras signal transduction: Involvement of Rho family proteins
44. Activation of Raf as a result of recruitment to the plasma membrane
45. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane
46. Raf revealed in life-or-death decisions
47. Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation
48. The complexity of Raf-1 regulation
49. Cell signalling. Raf gets it together
50. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis
51. Mutational activation of c-raf-1 and definition of the minimal transforming sequence
52. Regulation of Ras-mediated signaling: More than one way to skin a cat
53. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells
54. A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras
55. Structure and biological activity of human homologs of the raf/mil oncogene
56. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
57. Transformation of mammalian cells by constitutively active MAP kinase kinase
58. Interaction of activated Ras with Raf-1 alone may be sufficient for transformation of rat2 cells
59. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation
60. An essential role for Rac in Ras transformation
61. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
62. Phosphatidylinositol-3-OH kinase as a direct target of Ras
63. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf
64. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras
65. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product
66. Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets
67. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling
68. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway
69. Role of phosphatidylinositol 4,5-bisphosphate in Ras/Rac-induced disruption of the cortactin-actomyosin II complex and malignant transformation
70. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K
71. A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts
72. ras- and phosphatidylinositol 3′-kinase-dependent pathway
73. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor
74. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal
75. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
76. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB
77. PI3K: Downstream AKTion blocks apoptosis
78. PDGF- and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase
79. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
80. Regulation of cell death protease caspase-9 by phosphorylation
81. eIF4E activity is regulated at multiple levels
82. Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism
83. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1
84. Phosphoinositide kinases
85. Ras-dependent growth factor regulation of MEK kinase in PC12 cells
86. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis
87. Inhibition of serum- and ras-stimulated DNA synthesis by antibodies to phospholipase C
88. The regulation of AP-1 activity by mitogen-activated protein kinases
89. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways
90. R-Ras is regulated by activators and effectors distinct from those that control Ras function
91. M-Ras/R-Ras3, a transforming ras protein regulated by Sos1, GRF1, and p120 Ras GTPase-activating protein, interacts with the putative Ras effector AF6
92. Novel small GTPase M-Ras participates in reorganization of actin cytoskeleton
93. Epidermal-growth-factor receptors generate Ras GTP more efficiently than insulin receptors
94. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation
95. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation
96. Activation of c-Jun-NH2-kinase by UV irradiation is dependent on p21ras
97. ras-p21-induced cell transformation: Unique signal transduction pathways and implications for the design of new chemotherapeutic agents
98. Multiple ras effector pathways contribute to G(1) cell cycle progression
99. Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle
100. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras
101. Ras activation is necessary for integrin-mediated activation of extracellular signal-regulated kinase 2 and cytosolic phospholipase A2 but not for cytoskeletal organization
102. Distinct mechanisms mediate the initial and sustained phases of integrin-mediated activation of the Raf/MEK/mitogen-activated protein kinase cascade
103. R-Ras signals through specific integrin alpha cytoplasmic domains to promote migration and invasion of breast epithelial cells
104. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells
105. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines
106. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis
107. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype
108. Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct
109. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation
110. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice
111. Phase 1 and pharmacokinetic trial of ISIS 2503, a 20-Mer antisense oligonucleotide against H-RAS by 14-day continuous infusion in patients with advanced cancer
112. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras in combination with gemcitabine in patients with advanced cancer
113. Inhibition of purified p21ras farnesyl: Protein transferase by Cys-AAX tetrapeptides
114. Sequence dependence of protein isoprenylation
115. Sequence requirement for peptide recognition by rat brain p21ras protein farnesyl-transferase
116. Nonfarnesylated tetrapeptide inhibitors of protein farnesyltransferase
117. Protein farnesyltransferase: Kinetics of farnesyl pyrophosphate binding and product release
118. Human lamin B contains a farnesylated cysteine residue
119. The processing pathway of prelamin A
120. In vivo differential prenylation of retinal cyclic GMP phosphodiesterase catalytic subunits
121. Isoprenylation of a protein kinase. Requirement of farnesylation/alpha-carboxyl methylation for full enzymatic activity of rhodopsin kinase
122. PxF, a prenylated protein of peroxisomes
123. The gamma subunit of transducin is farnesylated
124. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
125. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development
126. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway
127. Inhibition of cell cycle progression and mitogenic signal transducers in vivo by farnesyltransferase inhibitor
128. SCH 66336 an orally bioavailable tricyclic farnesyl protein transferase inhibitor, demonstrates broad and potent in vivo antitumor activity
129. In vivo evaluation of farnesyltransferase inhibitor, PD169451
130. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
131. RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor with in vivo activity
132. Phase I and pharmacologic study with the novel farnesyltransferase inhibitor R115777
133. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule
134. A Phase I trial of the farnesyl transferase inhibitor SCH66336: Evidence for biological and clinical activity
135. Phase 1 and pharmacologic study of continuous daily oral SCH 66336, a novel farnesyl transferase inhibitor, in patients with solid tumors
136. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers
137. p21ras activation via hemopoietin receptors and c-kit requires tyrosine kinase activity but not tyrosine phosphorylation of p21ras GTPase-activating protein
138. A phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer
139. Use of farnesyl transferase inhibitor R115777 in relapsed and refractory acute leukemias: Preliminary results of a phase I trial
140. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
141. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice
142. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: Combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine
143. A phase I and pharmacokinetic (Pk) study of the farnesyltransferase inhibitor, R115777 in combination with gemcitabine (Gem)
144. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers
145. Phase I study of farnesyl transferase inhibitor SCH66336 with paclitaxel in solid tumors: Dose finding, pharmacokinetics, efficacy/safety
146. Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 in patients with advanced solid tumors
147. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors
148. Farnesyltransferase inhibitors and cancer treatment: Argeting simply ras?
149. Non-ras targets of farnesyltransferase inhibitors: Focus on Rho
150. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors
151. Farnesyltransferase inhibitors: Antineoplastic properties, mechanisms of action, and clinical prospects
152. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts
153. Both farnesylated and the geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice
154. The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis
155. Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro
156. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956
157. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines
158. Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors
159. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli
160. Inhibition of RAS-targeted prenylation: Protein farnesyl transferase inhibitors revisited
161. Inhibition of ras prenylation: A novel approach to cancer chemotherapy
162. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltranferase I inhibitor
163. Potent, highly selective, and non-thiol inhibitors of protein geranyl-geranyltransferase-I
164. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation
165. p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI298 through a transforming growth factor beta- and Sp1-responsive element: Involvement of the small GTPase rhoA
166. Farnesyltransferase inhibitors: Antineoplastic mechanism and clinical prospects
167. Inhibition of Ras prenylation: A novel approach to cancer chemotherapy
168. Bcl-2 targets the protein kinase Raf-1 to mitochondria
169. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
170. Phase I trial of ISIS 5132/ODN 698A, a 20-Mer phosphorothioate antisense oligonucleotide inhibitor of C-RAF kinase, administered by a 24-hour weekly intravenous (IV) infusion to patients with advanced cancer
171. Biological effects of cRaf1 kinase inhibitors
172. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
173. Characterization of HDJ-2, a human 40 kDa heat shock protein
174. Farnesylcysteine, a constituent of the alpha and beta subunits of rabbit skeletal muscle phosphorylase kinase: Localization by conversion to S-ethylcysteine and by tandem mass spectrometry